_version_ 1785092885779054592
author Hopcroft, Lorna
Wigmore, Eleanor M.
Williamson, Stuart C.
Ros, Susana
Eberlein, Cath
Moss, Jennifer I.
Urosevic, Jelena
Carnevalli, Larissa S.
Talbot, Sara
Bradshaw, Lauren
Blaker, Catherine
Gunda, Sreeharsha
Owenson, Venetia
Hoffmann, Scott
Sutton, Daniel
Jones, Stewart
Goodwin, Richard J. A.
Willis, Brandon S.
Rooney, Claire
DeBruin, Elza
Barry, Simon T.
author_facet Hopcroft, Lorna
Wigmore, Eleanor M.
Williamson, Stuart C.
Ros, Susana
Eberlein, Cath
Moss, Jennifer I.
Urosevic, Jelena
Carnevalli, Larissa S.
Talbot, Sara
Bradshaw, Lauren
Blaker, Catherine
Gunda, Sreeharsha
Owenson, Venetia
Hoffmann, Scott
Sutton, Daniel
Jones, Stewart
Goodwin, Richard J. A.
Willis, Brandon S.
Rooney, Claire
DeBruin, Elza
Barry, Simon T.
author_sort Hopcroft, Lorna
collection PubMed
description
format Online
Article
Text
id pubmed-10439172
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-104391722023-08-20 Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models Hopcroft, Lorna Wigmore, Eleanor M. Williamson, Stuart C. Ros, Susana Eberlein, Cath Moss, Jennifer I. Urosevic, Jelena Carnevalli, Larissa S. Talbot, Sara Bradshaw, Lauren Blaker, Catherine Gunda, Sreeharsha Owenson, Venetia Hoffmann, Scott Sutton, Daniel Jones, Stewart Goodwin, Richard J. A. Willis, Brandon S. Rooney, Claire DeBruin, Elza Barry, Simon T. NPJ Breast Cancer Author Correction Nature Publishing Group UK 2023-08-18 /pmc/articles/PMC10439172/ /pubmed/37596288 http://dx.doi.org/10.1038/s41523-023-00575-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Author Correction
Hopcroft, Lorna
Wigmore, Eleanor M.
Williamson, Stuart C.
Ros, Susana
Eberlein, Cath
Moss, Jennifer I.
Urosevic, Jelena
Carnevalli, Larissa S.
Talbot, Sara
Bradshaw, Lauren
Blaker, Catherine
Gunda, Sreeharsha
Owenson, Venetia
Hoffmann, Scott
Sutton, Daniel
Jones, Stewart
Goodwin, Richard J. A.
Willis, Brandon S.
Rooney, Claire
DeBruin, Elza
Barry, Simon T.
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
title Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
title_full Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
title_fullStr Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
title_full_unstemmed Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
title_short Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
title_sort author correction: combining the akt inhibitor capivasertib and serd fulvestrant is effective in palbociclib-resistant er+ breast cancer preclinical models
topic Author Correction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439172/
https://www.ncbi.nlm.nih.gov/pubmed/37596288
http://dx.doi.org/10.1038/s41523-023-00575-6
work_keys_str_mv AT hopcroftlorna authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels
AT wigmoreeleanorm authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels
AT williamsonstuartc authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels
AT rossusana authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels
AT eberleincath authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels
AT mossjenniferi authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels
AT urosevicjelena authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels
AT carnevallilarissas authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels
AT talbotsara authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels
AT bradshawlauren authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels
AT blakercatherine authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels
AT gundasreeharsha authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels
AT owensonvenetia authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels
AT hoffmannscott authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels
AT suttondaniel authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels
AT jonesstewart authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels
AT goodwinrichardja authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels
AT willisbrandons authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels
AT rooneyclaire authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels
AT debruinelza authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels
AT barrysimont authorcorrectioncombiningtheaktinhibitorcapivasertibandserdfulvestrantiseffectiveinpalbociclibresistanterbreastcancerpreclinicalmodels